These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 18176318)
1. Tenofovir DF plus lamivudine or emtricitabine for nonoccupational postexposure prophylaxis (NPEP) in a Boston Community Health Center. Mayer KH; Mimiaga MJ; Cohen D; Grasso C; Bill R; Van Derwarker R; Fisher A J Acquir Immune Defic Syndr; 2008 Apr; 47(4):494-9. PubMed ID: 18176318 [TBL] [Abstract][Full Text] [Related]
2. Raltegravir, tenofovir DF, and emtricitabine for postexposure prophylaxis to prevent the sexual transmission of HIV: safety, tolerability, and adherence. Mayer KH; Mimiaga MJ; Gelman M; Grasso C J Acquir Immune Defic Syndr; 2012 Apr; 59(4):354-9. PubMed ID: 22267017 [TBL] [Abstract][Full Text] [Related]
3. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. Gallant JE; DeJesus E; Arribas JR; Pozniak AL; Gazzard B; Campo RE; Lu B; McColl D; Chuck S; Enejosa J; Toole JJ; Cheng AK; N Engl J Med; 2006 Jan; 354(3):251-60. PubMed ID: 16421366 [TBL] [Abstract][Full Text] [Related]
4. Raltegravir-emtricitabine-tenofovir as HIV nonoccupational post-exposure prophylaxis in men who have sex with men: safety, tolerability and adherence. McAllister J; Read P; McNulty A; Tong WW; Ingersoll A; Carr A HIV Med; 2014 Jan; 15(1):13-22. PubMed ID: 24007390 [TBL] [Abstract][Full Text] [Related]
5. Optimal HIV Postexposure Prophylaxis Regimen Completion With Single Tablet Daily Elvitegravir/Cobicistat/Tenofovir Disoproxil Fumarate/Emtricitabine Compared With More Frequent Dosing Regimens. Mayer KH; Jones D; Oldenburg C; Jain S; Gelman M; Zaslow S; Grasso C; Mimiaga MJ J Acquir Immune Defic Syndr; 2017 Aug; 75(5):535-539. PubMed ID: 28696345 [TBL] [Abstract][Full Text] [Related]
6. Recent availability of two novel, fixed formulations of antiretroviral nucleoside analogues: a 12-month prospective, open-label survey of their practical use and therapeutic perspectives in antiretroviral-naive and -experienced patients. Manfredi R; Calza L AIDS Patient Care STDS; 2008 Apr; 22(4):279-90. PubMed ID: 18290748 [TBL] [Abstract][Full Text] [Related]
7. Assessment of adverse events associated with antiretroviral regimens for postexposure prophylaxis for occupational and nonoccupational exposures to prevent transmission of human immunodeficiency virus. Luque A; Hulse S; Wang D; Shahzad U; Tanzman E; Antenozzi S; Smith B Infect Control Hosp Epidemiol; 2007 Jun; 28(6):695-701. PubMed ID: 17520543 [TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic interactions between lersivirine and zidovudine, tenofovir disoproxil fumarate/emtricitabine and abacavir/lamivudine. Vourvahis M; Davis J; Langdon G; Layton G; Fang J; Choo HW; Hansson AG; Tawadrous M Antivir Ther; 2013; 18(6):745-54. PubMed ID: 23558061 [TBL] [Abstract][Full Text] [Related]
9. The use of a triple nucleoside-nucleotide regimen for nonoccupational HIV post-exposure prophylaxis. Winston A; McAllister J; Amin J; Cooper DA; Carr A HIV Med; 2005 May; 6(3):191-7. PubMed ID: 15876286 [TBL] [Abstract][Full Text] [Related]
10. Efficacy of pegylated interferon plus ribavirin treatment in HIV/hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone. Mira JA; López-Cortés LF; Barreiro P; Tural C; Torres-Tortosa M; de Los Santos Gil I; Martín-Rico P; Ríos-Villegas MJ; Hernández-Burruezo JJ; Merino D; López-Ruz MA; Rivero A; Muñoz L; González-Serrano M; Collado A; Macías J; Viciana P; Soriano V; Pineda JA J Antimicrob Chemother; 2008 Dec; 62(6):1365-73. PubMed ID: 18854330 [TBL] [Abstract][Full Text] [Related]
11. Tenofovir or zidovudine in three-drug combination therapy with one nucleoside reverse transcriptase inhibitor and one non-nucleoside reverse transcriptase inhibitor for initial treatment of HIV infection in antiretroviral-naïve individuals. Spaulding A; Rutherford GW; Siegfried N Cochrane Database Syst Rev; 2010 Oct; (10):CD008740. PubMed ID: 20927777 [TBL] [Abstract][Full Text] [Related]
12. Non-occupational HIV post-exposure prophylaxis at a Sydney metropolitan sexual health clinic. Gulholm T; Jamani S; Poynten IM; Templeton DJ Sex Health; 2013 Nov; 10(5):438-41. PubMed ID: 23962489 [TBL] [Abstract][Full Text] [Related]
13. Tenofovir DF and emtricitabine vs. zidovudine and lamivudine. Laessig KA; Lewis LL; Hammerstrom TS N Engl J Med; 2006 Jun; 354(23):2506-8; author reply 2506-8. PubMed ID: 16760455 [No Abstract] [Full Text] [Related]
15. Cost-effectiveness analysis of emtricitabine/tenofovir versus lamivudine/zidovudine, in combination with efavirenz, in antiretroviral-naive, HIV-1-infected patients. Sánchez-de la Rosa R; Herrera L; Moreno S Clin Ther; 2008 Feb; 30(2):372-81. PubMed ID: 18343275 [TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of nucleoside reverse transcriptase inhibitor pairs in efavirenz-based regimens for treatment-naïve adults with HIV infection in the United States. Brogan AJ; Talbird SE; Cohen C Value Health; 2011; 14(5):657-64. PubMed ID: 21839403 [TBL] [Abstract][Full Text] [Related]
17. Safety and Tolerability of Once Daily Coformulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide for Postexposure Prophylaxis After Sexual Exposure. Mayer KH; Gelman M; Holmes J; Kraft J; Melbourne K; Mimiaga MJ J Acquir Immune Defic Syndr; 2022 May; 90(1):27-32. PubMed ID: 34991141 [TBL] [Abstract][Full Text] [Related]